Kornimate/medical-research-clean huggingface dataset:
collection of blood from patients with pancytopenia

Conditions: Pancytopenia

Summary: aplastic anemia is a condition in which the cells normally found in blood are greatly decreased. the normal levels of white blood cells, red blood cells, and platelets are much lower in patients with aplastic anemia. because of these low levels of blood cells, patients with aplastic anemia have a variety of immune system abnormalities. however, low levels of blood cells make it difficult to collect specialized white blood cells (mononuclear cells) for research studies. this study was designed to collect lymphocytes from patients with low levels of all blood cells (pancytopenia) for use in research. patients participating in the study will undergo a special procedure known as lymphapheresis. during lymphapheresis blood is taken from the patient in a manner similar to blood donation. the white blood cells are selectively removed by spinning (centrifugation), and the remaining red blood cells and platelets are placed back (re-infused) into the donor s blood stream. patients participating in this study will not benefit directly from it. however, cells collected in this study may increase scientific knowledge and improve understanding and treatment for diseases like aplastic anemia.

patients with aplastic anemia, myelodysplasia, and other marrow failure syndromes have a variety of immunologic abnormalities including lymphocyte phenotypic and lymphokine production dysregulation. because of their low blood counts, it has been difficult to obtain sufficient peripheral blood mononuclear cells for research studies. patients agreeing to this protocol will be lymphapheresed the equivalent of one or two units of cells (approximately 1-2 x 10(8) cells), which will be used for research purposes.

Eligibility criteria:
* inclusion criteria: all patients with aplastic anemia or other bone marrow failure in which we would not expect to obtain 1 x 10(8) mononuclear cells from 100 mls of peripheral blood (i.e. an absolute lymphocyte count approximately less than 2000 per mm(3)). age greater than or equal to 18. exclusion criteria: patients unable to comprehend the investigational nature of the procedure. patients unable to tolerate a temporary reduction of blood volume the equivalent of one unit of blood.

Keywords: bone marrow failure lymphocytapheresis pancytopenia aplastic anemia hematosuppressive disease
colorectal cancer screening in xinxiang city

Conditions: Colorectal Cancer

Summary: the primary objective of this study is to evaluate the sensitivity of the fecal protein dual-index test reagent for the detection of colorectal cancer (crc).

the project uses fecal hemoglobin and transferrin dual-index combined with reagents that can be self-tested at home (referred to as fecal protein dual-index detection reagents), combined with colorectal cancer risk factor questionnaires, to carry out colorectal cancer screening in people of specific ages in the city, aiming to achieve early screening, early diagnosis and early treatment, and evaluate the effect of fecal protein dual-index detection reagents in early screening of colorectal cancer, so as to provide a scientific basis for optimizing the national screening program.

Eligibility criteria:
inclusion criteria: 1. subjects aged 45-74 years at time of consent 2. have not had gastrointestinal resection exclusion criteria: 1. previous history of colorectal cancer 2. patients who have been confirmed to have other malignant neoplastic diseases of the digestive system 3. patients with severe heart, brain, lung disease or liver and kidney dysfunction or insufficiency 4. those with severe mental disorders and language communication disorders 5. history of contraindications to colonoscopy 6. pregnant women
post-acute care for patients with frailty

Conditions: Frailty; Retrospective Study

Summary: acute illness could be enormous stress for frail people. combining comprehensive geriatric assessment and multifactorial intervention has positive effects on frail community older adults. however, few studies investigated the effects of post-acute care (pac) in frail older patients who just recovered from acute hospitalization. this study aimed to evaluate the effects of pac on frail older adults in taiwan.

frail patients aged \>= 75 were recruited and divided into pac or control groups. the pac group received comprehensive geriatric assessment (cga) and multifactorial intervention for two to four weeks. the control group received cga only. the primary outcomes were 90-day emergency room visits, readmissions, and mortality after pac.

Eligibility criteria:
inclusion criteria: 1. mild to severe frailty identified by the clinical frailty scale 2. age ≥ 75 years 3. diagnosis with parkinson's disease, dementia, chronic obstructive pulmonary disease, or chronic kidney disease stage three or worse 4. acute hospital stays between 3 to 30 days with deconditioning 5. stable medical condition with no need of intensive care, laboratory examination, or oxygen dependence exclusion criteria: 1. refused to participate in the program 2. candidate for other post-acute care programs (i.e. stroke, traumatic neurological injury, or fracture) 3. unable to cooperate with the program due to mental or cognitive impairment 4. long-term ventilator-dependence 5. long-term bed-ridden status (\> 6 months) 6. diagnosed as end of life and in need of palliative care 7. diagnosed as major illness (i.e. end-stage renal disease) and in need of frequent inpatient treatment ( \> 3 times over recent 6 months) 8. institutional residents 9. home medical care participants
lactoferrin treatment in hiv patients

Conditions: HIV Infection

Summary: our general goal is to evaluate the potential effectiveness of recombinant lactoferrin (1500mg bid) for reducing inflammation among hiv positive participants.


Eligibility criteria:
inclusion criteria: 1. hiv-positive participants receiving antiretroviral therapy (art) for \>1 year 2. hiv rna level \<200 copies/ml for at least 6 months (≥2 separate values) 3. age \>40 years exclusion criteria: 1. prior cardiovascular disease or stroke 2. diabetes 3. rheumatologic diseases 4. pregnancy 5. chronic kidney disease, stage iv or v (creatinine clearance \<30 ml/min/1.73m2) 6. cirrhosis or end-stage liver disease
the desensitization therapy with gb-0998 for anti-donor antibody-positive recipients.

Conditions: End Stage Renal Disease

Summary: it is intended to examine the safety and efficacy of desensitization therapy by gb-0998 (intravenous immunoglobulin) for the anti-donor antibody positive recipient in need of pre-transplant desensitization. patients with positive fcxm-t after performing twice double filtration plasmapheresis (dfpp) therapy will receive gb-0998 1g/kg/day for four days.


Eligibility criteria:
inclusion criteria: * patients with stage 4 or 5 on the ckd classification. * of the patients that wants a living-donor kidney transplant of abo blood type compatible, patients with positive fcxm-t and negative cdc-t to the donor. * patients with positive fcxm-t after performing twice dfpp therapy exclusion criteria: * patients who had taking to continue immunosuppressive drugs or steroids within 4 weeks before obtaining informed consent. * patients who had ivig therapy, or plasmapheresis therapy within 12 weeks before to informed consent. * patients who had rituximab within 6 month before to informed consent. * patients who have undergone splenectomy. * patients with severe hepatic disorder or severe heart disorder. * patients with receiving treatment of malignancy. * patients with high risk of thromboembolism. * patients with history of shock or hypersensitivity to gb-0998. * patients with hereditary fructose intolerance or iga deficiency. * patients with pregnant or probably pregnant.

Keywords: ivig renal transplantation desensitization
screening for cystic fibrosis and cystic fibrosis related disorders in chinese adults with bronchiectasis

Conditions: Cystic Fibrosis, Pulmonary

Summary: the study carries out sweet tests and cftr-mutation screening to explore the prevalence, clinical characteristics, and prognosis of cystic fibrosis, as well as the cftr-mutation spectrum in chinese adults with bronchiectasis. the study is multi-centered, prospective, non-interventional, and observational.

the incidence of cystic fibrosis (cf) or cftr dysfunction in china remains unclear due to the absence of a diagnosis and different genetic backgrounds. however, the cf case rate in western countries is relatively high, up to 1/2500. according to the limited statistics, the most common classic clinical symptom of chinese cf patients is bronchiectasis. other symptoms often seen in diseased western groups, such as pancreatic insufficiency, are rarely seen in chinese patients. thus, chinese cf or cftr dysfunction patients easily misdiagnose bronchiectasis, chronic pneumonia, asthma, etc. sweet test and cftr-mutation screening are urgently needed for diagnosing and treating cf or cftr dysfunction patients in chinese adults with bronchiectasis. the study will focus on the change in cftr function, genetic susceptibility factors, and disease progression to explore the incidence, clinical characteristics, and prognosis of cystic fibrosis, as well as the cftr mutation spectrum in chinese adults with bronchiectasis.

Eligibility criteria:
inclusion criteria: * age\>18 years, the diagnosis of bronchiectasis needs a reference to the definition of "non-cystic fibrosis bronchiectasis guideline" published by the british thoracic society in 2017 or 2021 china bronchiectasis expert consensus, clinical symptoms of cough and expectoration, with or without intermittent hemoptysis, and chest ct showed bronchiectasis * patients who are willing to sign the consent form and participate in the study. exclusion criteria: * patients with incomplete essential information, which is needed for the integrity of data analysis. essential information includes ct images, respiratory sample cultures, spirometry, and exacerbation history for at least one year. * patients under 18 years old. sweat test exclusion criteria: * patients with an implanted device, such as a defibrillator, neurostimulator, pacemaker, or ecg monitor. * patients with a history of epilepsy or seizures. * patients who are pregnant. * patients that have a known sensitivity or allergy to any ingredient. * over-damaged, denuded skin or other recent scar tissue. * patients with cardiac conditions or with suspected heart problems.
clinical study to investigate the biological activity, safety, tolerability, and pharmacokinetics of act-334441 in subjects with systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus

Summary: international trial to evaluate the biological activity and safety of cenerimod (act-334441) in systemic lupus erythematosus (sle) patients.

this multicentre, double-blind, placebo-controlled study will have a staggered approach (part a and b). in part a, eligible patients will be randomly assigned (1:1:1:1) to once daily oral administration of cenerimod (0.5, 1, 2 mg) or placebo. after all patients have completed 4 weeks of treatment during part a, an independent data monitoring committee will review non-blinded data in an interim analysis to evaluate the safety profile of cenerimod and recommend whether the study could proceed to part b. in part b, additional patients will be randomized (3:1) to once daily oral administration of cenerimod 4 mg or placebo. all participants will receive study medication for 12 weeks.

Eligibility criteria:
inclusion criteria: * male and female participants aged 18 to 65 years with established sle. participants must have active sle, systemic lupus erythematosus disease activity index-2000 (sledai-2k) score of at least 2 points for musculoskeletal or mucocutaneous manifestations and history or presence at screening of positive anti-nuclear antibodies (ana) or anti-double-stranded dna (anti-dsdna) antibodies. * enrolled participants must be treated with background sle medications. exclusion criteria: * participants with significant medical conditions or therapies for such conditions (e.g., cardiovascular, pulmonary, immunological, hepatic, ophthalmological, infection and infection risks, history or presence of malignancy, history or presence of bone marrow or solid organ transplantation) or lactating or pregnant women. * participants with severe sle disease or with clinically relevant medical or surgical conditions that, in the opinion of the investigator, would put the subject at risk by participating in the study.

Keywords: systemic lupus erythematosus
molecular & clinical evaluation of low hdl syndromes

Conditions: Cardiovascular Diseases; Heart Diseases; Atherosclerosis

Summary: to study the genetic cause of low hdl-c, a risk factor for premature atherosclerotic vascular disease in patients with normal total cholesterol. the focus is primarily on the identification of a single mutation, as has been demonstrated in one family.

background: low levels of high density lipoprotein cholesterol (hdl-c) have been found to be associated with an increased risk for coronary artery disease (cad). however, the genetic basis for this association is not well understood and the clinical implications of this association have not been extensively addressed. the study, in seeking to elucidate the genetic basis for low hdl-c and examine the clinical implications of low hdl-c, focuses upon an important research topic. design narrative: specific aims of the study include: 1) collection and characterization of plasma and dna from probands with very low hdl-c. linkage analysis will be performed using highly polymorphic markers within or near hdl-c candidate genes. the hypothesis to be tested is that polymorphic microsatellites segregate with the low hdl-c phenotype. 2) further genetic characterization of families evidence of linkage to specific hdl-c candidate genes identified in specific aim 1. the hypothesis to be tested is that structural variants in hdl-c candidates are responsible for low hdl-c. 3) evaluate the physiologic significance of novel genomic variants identified in specific aim 2. the hypothesis to be tested is that structural variants will affect expression of the gene product. 4) examine early atherosclerosis in low hdl-c syndromes. the hypothesis to be tested is that increased carotid intima-medial thickness is prevalent with isolated low hdl-c.

Eligibility criteria:
no eligibility criteria
compassion strikes back

Conditions: LVAD Caregivers; LVAD (Left Ventricular Assist Device); Quality of Life (QOL); Self-Compassion

Summary: research has shown that lvad patients and their caregivers typically experience increased mental health concerns and decreased quality of life following lvad implantation and hospital discharge. the purpose of this study is to explore how to improve quality of life for lvad patients and their caregivers in the initial transition from hospital to home after lvad implantation. over the course of the study, participants will complete 2 surveys: one when participants are in the hospital and one at a 2-month post-hospital follow-up appointment with the participants' cardiologist. participants may be contacted if there is data missing from surveys. participants may also be provided with information on improving mental health in the form of handouts or a brief meeting with a psychology provider.


Eligibility criteria:
inclusion criteria: * lvad implantation or caregiver or patient with lvad; over 18 years old; primary caregiver is a family member exclusion criteria: * currently or in the past 3 months received psychotherapy or psychosocial or peer support; hospitalized for psychiatric reasons in the past 6 months; current, active suicidal thoughts or a reported suicide attempt within the past year; a current alcohol/substance use disorder that required immediate treatment; or a current or past thought disorder, psychosis, or unmanaged bipolar disorder; enrolled in another investigational research/clinical trial; toxic/negative dynamic between pt and caregiver; extended post-lvad implantation course (i.e., more than 2 months in the hospital).
comparison of video-based versus written patient education on melanoma

Conditions: Melanoma; Malignant Melanoma

Summary: the purpose of this study is to compare the effect of video-based patient education with written instruction on subjects' understanding of melanoma.

we plan to conduct a randomized, controlled trial comparing the effect of video-based patient education with written instruction on subjects' understanding of melanoma. subjects randomized to the video-based education arm will be instructed to watch a video on the definition of melanoma, risk factors associated with the development of melanoma, and signs that should prompt an evaluation for melanoma. subjects randomized to the written education arm will receive written information on the definition of melanoma, risk factors associated with the development of melanoma, and signs that should prompt an evaluation for melanoma. the contents of the video and the written educational materials will be comparable. at the end of the study period 1 month later, subjects will be interviewed via telephone regarding their understanding of melanoma. subjects will also be interviewed regarding their comprehension and attitude towards video-based and written education materials.

Eligibility criteria:
inclusion criteria: * 18 years of age or older at time of consent, may be men or women. * able to adhere to the study visit schedule and other protocol requirements. * capable of giving informed consent. exclusion criteria: * non-english speaking individuals.

Keywords: patient education dermatology patient education melanoma melanoma education malignant melanoma melanoma detection
how acupuncture therapy improves dysphagia in parkinson's patients

Conditions: Dysphagia

Summary: this study is focusing on dysphagic participants with parkinson's disease. the aim of our study is to evaluate the effectiveness of acupuncture therapy as an additional intervention for these participants. participants were randomly assigned to either the experimental group or the control group, with 56 individuals in each group. both groups are receiving standard treatment and swallowing rehabilitation training, while the experimental group is also receiving acupuncture therapy. our study aims to provide valuable insights into the potential benefits of acupuncture in improving swallowing difficulties in parkinson's disease participants.

this study is focusing on dysphagic participants with parkinson's disease. the aim of our study is to evaluate the effectiveness of acupuncture therapy as an additional intervention for these participants. participants were randomly assigned to either the experimental group or the control group, with 56 individuals in each group. both groups are receiving standard treatment and swallowing rehabilitation training, while the experimental group is also receiving acupuncture therapy. our study aims to provide valuable insights into the potential benefits of acupuncture in improving swallowing difficulties in parkinson's disease participants. the study lasted 42 days (6 weeks) for each participant. specifically, our main focus is on the study of lianquan, shanglianquan (depression between the hyoid bone and the lower border of the mandible), yifeng, fengchi, wangu, fengfu, yamen, neidaying (depression of 1 inch below the anterior margin of the mandible), jinjin, yuye, posterior pharyngeal wall (both sides of the uvula).

Eligibility criteria:
inclusion criteria: * age \>18 years. * meeting the diagnostic criteria for parkinson's disease. * diagnosed with dysphagia confirmed by the video fluoroscopic swallowing study. * water swallow test\> level 3. * stable vital signs, conscious, able to cooperate with assessment and treatment. exclusion criteria: * dysphagia possibly caused by other reasons, such as cerebrovascular disease, trauma, neuromuscular diseases, malignant diseases of the pharynx and larynx, and digestive tract diseases. * history of mental diseases or use of antipsychotics. * complicated with cognitive impairment or consciousness dysfunction. * simultaneously suffering from severe liver, kidney failure, tumors, or hematological diseases.
evaluation of subcutaneous desferrioxamine as treatment for transfusional hemochromatosis

Conditions: Anemia (Iron-Loading); Beta-Thalassemia; Hematologic Diseases; Hemoglobinopathies; Thalassemia; Iron Overload; Hemochromatosis

Summary: to determine whether deferoxamine prevented the complications of transfusional iron overload.

background: the prognosis of congenital or long-term anemia was formerly limited by the complications of blood transfusion, splenectomy, or infection, problems now largely overcome by sophisticated clinical care. lifespan is now determined by the rate of myocardial iron deposition, with death occurring from cardiac failure or arrhythmia, usually between the ages of 15 and 25. endocrine complications and hepatic enlargement are also evident by this age. deferoxamine increases urinary iron excretion and is the only chelator currently available for chronic administration. daily administration of deferoxamine results in negative iron balance in most patients by the age of 10; this study was designed to determine whether the onset of cardiac complications was delayed and life prolonged by iron removal. this trial began in 1978. its forerunner was a study involving both deferoxamine and ascorbic acid. although ascorbic acid promotes iron removal, its administration was followed by cardiac deterioration in several patients. in this study, patients receiving subcutaneous deferoxamine were randomized to receive either ascorbic acid or placebo, thereby providing a controlled test of this agent in treatment of iron overload. sixty-five patients with homozygous beta-thalassemia participated in the long-term chelation trial. of these, 49 were randomized to the ascorbic acid trial. several noninvasive techniques have been developed to evaluate organ function in iron-overloaded patients, thereby facilitating the assessment of chelation therapy. these techniques included chest x-rays, electrocardiograms, echocardiograms, and 24-hour holter monitoring to assess cardiac function. liver function was evaluated by standard liver function tests, cat scan, and live biopsy. during the last six years of the study, hepatic iron stores were measured magnetically with a dual channel superconducting quantum-interference susceptomer. endocrine function was also assessed by standard tests. design narrative: all patients received subcutaneous deferoxamine and iron removal was determined by measurement of serum ferritin and periodic non-invasive measurements of liver iron concentration. clinical status was evaluated by non-invasive testing of cardiac and endocrine function. the study completion date listed in this record was inferred from the last publication listed in the citations section of this study record.

Eligibility criteria:
males and females, 5 years or older, with transfusional hemochromatosis.
rajavithi health promotion project (population base cohort)

Conditions: Diabetes Mellitus; Hypertension; Dyslipidemia; Obesity; Cardiovascular Disease; Coronary Artery Disease

Summary: metabolic syndrome (hypertension, diabetes mellitus, obesity, cerebrovascular-cardiovascular disease) in community survey was performed in central bangkok. prospective cohort and intensive educated intervention (health promotion program in specific high risk groups) were performed. the aim of the study is to identify high risk patients who can develop serious complications from metabolic syndrome. an analysis of health outcomes in multiple dimensions will be performed.


Eligibility criteria:
inclusion criteria: * age 16 years or more * informed consent * living in selected community (health promotion area of rajavithi hospital)

Keywords: dm ht dyslipidemia obesity cardiovascular disease cerebrovascular disease myocardial infarction stroke metabolic syndrome cvd-cad